Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
BACKGROUND: To determine prognostic factors for local control in the radiotherapeutic management of non-metastatic Ewing sarcoma. PROCEDURE: Forty patients with localized Ewing sarcoma (ES) were treated with primary site RT at one institution. Median RT dose was 55.8 Gy (range, 25.5-76 Gy). Chemothe...
| Publicado en: | Pediatric Blood & Cancer Vol. 49; no. 2; pp. 145 - 149 |
|---|---|
| Autores principales: | , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Aug2007
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105922993&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105922993 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15455009 1XL2 jtl: Pediatric Blood & Cancer issn: 15455009 maglogo: Y pubinfo: dt: Aug2007 vid: 49 iid: 2 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 105922993 105922993 2009615898 10.1002/pbc.20904 NLM16732580 105922993 ppf: 145 ppct: 4 formats: tig: atl: Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. aug: au: Paulino AC Nguyen TX Mai WY Teh BS Wen B affil: Department of Radiology, Division of Radiation Oncology, Baylor College of Medicine, Houston, Texas. sug: subj: Bone Neoplasms Radiotherapy Radiotherapy Methods Sarcoma, Ewing's Radiotherapy Adolescence Adult Antineoplastic Agents, Combined Administration and Dosage Antineoplastic Agents, Combined Therapeutic Use Chemotherapy, Adjuvant Child Child, Preschool Cox Proportional Hazards Model Cyclophosphamide Administration and Dosage Dosage Forms Methods Doxorubicin Administration and Dosage Etoposide Administration and Dosage Female Ifosfamide Administration and Dosage Kaplan-Meier Estimator Male Middle Age Multivariate Analysis Radiation Dosage Regression Sarcoma, Ewing's Drug Therapy Survival Treatment Outcomes United States Vincristine Administration and Dosage Human Adolescent: 13-18 years Adult: 19-44 years Child: 6-12 years Child, Preschool: 2-5 years Middle Aged: 45-64 years Female Male ab: BACKGROUND: To determine prognostic factors for local control in the radiotherapeutic management of non-metastatic Ewing sarcoma. PROCEDURE: Forty patients with localized Ewing sarcoma (ES) were treated with primary site RT at one institution. Median RT dose was 55.8 Gy (range, 25.5-76 Gy). Chemotherapy was given to 34 patients (85%) with the most common regimen being vincristine, dactinomycin, cyclophosphamide, doxorubicin alternating with ifosfamide and etoposide (VACA + IE) in 10. Median follow-up for surviving patients was 12.3 years (range, 1.7-26.4 years). RESULTS: The 5- and 10-year local control rate was 78.2%. On multivariate analysis, RT dose was the only prognostic factor to impact on local control. The 5- and 10-year local control rate was 88.7% for RT dose >/=49 Gy and was 37.5% for <49 Gy (P = 0.0002, log-rank test). For tumors </=8 cm, the 5- and 10-year local control rate was 94.1% for RT dose >/=49 Gy and 50.0% for RT dose <49 Gy (P = 0.01, log-rank test). For tumors >8 cm, the 5- and 10-year local control rate was 85.7% for RT dose >/=54 Gy and 26.7% for RT dose <54 Gy (P = 0.006, log-rank test). CONCLUSIONS: Radiotherapy dose was found to influence local control in ES. In particular, patients who received RT doses >/=49 Gy for tumor size </=8 cm and >/=54 Gy for tumor size >8 cm had improved local control. Pediatr Blood Cancer 2007;49:145-148. (c) 2006 Wiley-Liss, Inc. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|